

UC San Diego

UC San Diego Previously Published Works

Title

Associations of diabetes mellitus and other cardiovascular disease risk factors with decline in the ankle-brachial index

Permalink

<https://escholarship.org/uc/item/6hk2d965>

Journal

Vascular Medicine, 19(6)

ISSN

1358-863X

Authors

Forbang, Nketi I
McDermott, Mary M
Liao, Yihua
[et al.](#)

Publication Date

2014-12-01

DOI

10.1177/1358863x14554033

Peer reviewed



Published in final edited form as:

Vasc Med. 2014 December ; 19(6): 465–472. doi:10.1177/1358863X14554033.

Associations of Diabetes Mellitus and Other Cardiovascular Disease Risk Factors with Decline in the Ankle Brachial Index

Nketi I. Forbang, MD^a, Mary M. McDermott, MD^b, Yihua Liao, MS^b, Joachim H. Ix, MD, MAS^a, Matthew A. Allison, MD, MPH^a, Kiang Liu, PhD^b, Lu Tian, ScD^c, Natalie Evans, MD^d, and Michael H. Criqui, MD, MPH^a

^aUniversity of California, San Diego, San Diego, CA

^bNorthwestern University, Chicago, IL

^cStanford University, Stanford, CA

^dCleveland Clinic, Cleveland, OH

Abstract

Objectives—We compared associations of diabetes mellitus (DM) and other cardiovascular disease (CVD) risk factors with decline in the ankle brachial index (ABI) over four years in participants with and without peripheral artery disease (PAD).

Methods—Five hundred sixty-six participants, 300 with PAD, were followed prospectively for four years.

Results—Mean (SD) baseline ABI values were 0.70 (0.13) for participants with both PAD and DM, 0.67 (0.14) for participants with only PAD, 1.10 (0.13) for participants with only DM, and 1.10 (0.10) for participants with neither PAD nor DM. After adjusting for age, gender, and baseline ABI, corresponding ABI change from baseline to 4-year follow-up were -0.02, -0.04, +0.05, and +0.05 respectively. Compared to participants with neither PAD nor DM, participants with only PAD showed significantly more ABI decline ($P < .01$), while the decline in participants with both PAD and DM was borderline non-significant ($P = .06$). After adjustments for baseline ABI, age, gender, African-American ethnicity, and other cardiovascular disease (CVD) risk factors; independent factors associated with ABI decline in participants with PAD in the lower ABI leg were older age and elevated D-dimer. DM was not related to ABI decline.

Conclusions—Despite being an important risk factor for PAD, DM was not independently associated with ABI decline. This could reflect the effect of DM promoting both PAD and lower extremity arterial stiffness, resulting in a small decline in the ABI over time. In conclusion, ABI change over time in persons with diabetes may not accurately reflect underlying atherosclerosis.

Corresponding Author: Nketi I. Forbang, University of California, San Diego, CA, Division of Preventive Medicine, 8950 Villa La Jolla Drive, Suite A206, San Diego, CA 92037, Mail Code #0965, Phone: +011 858-822-7680, Fax: +011 858-822-7662, nforbang@gmail.com.

Conflict of Interests Statement

The authors declare that there is no conflict of interests.

Keywords

Peripheral artery disease; Ankle brachial index; Diabetes

Introduction

The ankle brachial index (ABI) is the ratio of systolic blood pressure (SBP) at the ankle divided by SBP at the arm, and is a standard primary diagnostic tool used to identify individuals with peripheral artery disease (PAD).¹ A low ABI (< 0.90) has good sensitivity and excellent specificity for detecting PAD compared to the angiographic gold standard.² Compared to individuals with a normal ABI (0.90–1.30), individuals with PAD have poorer physical functioning, more rapid mobility loss, greater functional decline, and have an increased risk of incident cardiovascular events.^{3–8}

Diabetes mellitus (DM) is an important risk factor for PAD, including limb loss, but also can be associated with stiff lower extremity arteries.^{9–11} Stiff ankle arteries lead to falsely-normal or high ABI values (ABI > 1.3) since, in this setting, the measured ankle SBP may reflect arterial wall stiffness rather than just the inter-arterial blood pressure. Thus, DM could promote lowering of the ABI due to atherosclerosis, or increase the ABI due to stiff vessels. This dichotomy may limit the prognostic value of the ABI in diabetic patients.

Few studies have evaluated longitudinal decline in the ABI in patients with PAD. ABI decline may serve as an important marker for adverse PAD outcomes. The aim of this study was to determine characteristics associated with ABI decline over time, with a primary focus on DM.

Methods

Study Participants

We studied individuals from the Walking and Leg Circulation Study (WALCS) and WALCS II cohorts.¹² WALCS consisted of 740 participants (age 55 or older) with and without PAD recruited between October 1998 and January 2000. WALCS II included 414 WALCS participants attending their fourth-annual visit and 425 newly identified persons (age 59 or older) with and without PAD enrolled between November 2002 and May 2004.¹³ In both WALCS and WALCS II, persons with PAD were identified from consecutive patients diagnosed with PAD from three Chicago-area non-invasive vascular laboratories. Participants without PAD were identified from among consecutive patients with normal lower extremity arterial testing identified from the same three Chicago-area noninvasive vascular laboratories, and from a large general internal medicine practice at Northwestern Medical Center. Participants attended a baseline study visit, and returned for annual follow-up. The Institutional Review Board at Northwestern University and Catholic Health Partners Hospital approved the protocol. All participants gave informed consent.

Exclusion criteria

Exclusion criteria for both WALCS cohorts have been reported.^{6,14} Participants with dementia, knee amputations (above or below the knee) and recent major surgery (within 30 days), were excluded from this study. Participants who did not speak English, were confined to a wheel chair, or resided in a nursing home were also excluded from participation.

Ankle-brachial index

Systolic pressures in the bilateral brachial, dorsalis pedis and posterior tibial arteries were measured twice with a hand-held Doppler probe (Nicolet Vascular Pocket Dop II, Nicolet Biomedical, Golden, Colorado). The ABI was calculated by dividing the mean of the dorsalis pedis and posterior tibial pressures in each leg by the mean of all 4 brachial pressures. Because of possible subclavian stenosis, when one brachial artery pressure was greater than the opposite brachial arterial pressure in both measurement sets and the right and left brachial arterial pressures differed by at least 10mm Hg, the average brachial pressures in the arm with the highest pressure were used to calculate the ABI for both legs.¹⁵ PAD was defined as an ABI < 0.90. The lower of the right and left ABI values was used to determine PAD status.

Co-morbidity and risk factor assessments

Information was obtained from patient report, physical examination, laboratory values, primary care physician questionnaire, and assays of venous blood. Number of cardiovascular diseases was determined using established co-morbidity algorithms from the Women's Health and Aging Study (i.e. DM, hypertension, myocardial infarction, stroke, and heart failure).¹⁶ Cigarette smoking history was obtained from patient self-report. Participants brought in their medication bottles to ascertain medication use. Baseline measurements of height and weight were used to calculate body mass index (BMI) as (weight [kg]/height [m]²).

D-Dimer and C-reactive Protein (CRP)

Blood specimens were collected and stored at 70°C until the time of measurement. An Asserachrom D-Di kit (Diagnostica Stago, Parsippany, New Jersey) was used to measure D-dimer using an ELISA procedure. The Asserachrom D-Di kit has a lower detection limit of 5 ng/ml. Concentrations of high-sensitivity CRP were determined using an immunoturbidimetric assay on the Hitachi 917 analyzer (Roche Diagnostics, Indianapolis, Indiana), using reagents and calibrators from Denka Seiken (Niigata, Japan). This assay has a sensitivity of 0.003 mg/dl.

Total and HDL cholesterol

Total cholesterol was measured with an enzymatic reaction (peroxidase/phenol-4-amioiphenazone indicator reaction).¹⁷ High-density lipoprotein (HDL) cholesterol was measured with direct enzymatic colorimetric assay.¹⁸

Leg symptoms

The San Diego Claudication Questionnaire was used to classify PAD participants into one of four groups based on leg symptoms.¹⁹ The categories are as follows: 1 -asymptomatic; 2 - intermittent claudication (IC, calf pain on exertion that does not begin at rest, causes the participant to stop walking, and resolves within ten minutes of rest); 3 -leg pain on exertion and rest (different from critical limb ischemia [leg pain at rest, ulcers, or gangrene]); 4 - atypical leg pain on exertion.^{12,20}

Statistical analysis

Our analysis includes 566 participants mostly of Caucasian and African Americans [there were low frequencies of Hispanic, and Asian American ethnicity] who had ABI at baseline and at four-year follow up. Our study sample size was derived in the following steps; the first step presented the initial cohort; the second step excluded limbs without our outcome (ABI change between baseline and four year follow up); and the final step excluded limbs with revascularization (either prior to baseline, or during four year follow up. We excluded 240 limbs with revascularization prior to or during follow up. Combining WALCS and WALCS II together, there were 489 (312 + 177) lower ABI legs, and 555 (358 + 197) higher ABI legs. Also, there were 77 participants with higher ABI legs, but not lower ABI legs, and 11 participants with lower ABI legs, but not higher ABI legs in our analysis. This resulted in our current study sample of 566 participants contributing 1044 limbs free from revascularization. Limbs with revascularization during four year follow up period were included in time to event (interval censoring) analyses for the composite endpoint of ABI decline ≥ 0.15 or revascularization. The latter analysis resulted in a larger sample size of 956 participants.

Cohort characteristics were summarized by mean (SD), for continuous variables, and proportions (N) for categorical variables. Participants were assigned to four groups; both PAD and DM, only PAD, only DM, and neither PAD nor DM. Linear regression models were used to compare ABI change from baseline to year 4 in all four groups. Time to event (interval censoring) analyses were used to determine the likelihood of the combined outcome of ABI decline ≥ 0.15 or revascularization. For both linear regressions and time to event analyses, participants with neither PAD nor DM were the reference group, and adjustments were made for baseline ABI, age, and gender. Stepwise selection multivariable linear regression models ($p < 0.1$ criterion) was used to determine independent associations of ABI change, first for the entire cohort, and then stratified by PAD status. Baseline ABI, age, gender, African American ethnicity, body mass index (BMI), cigarette smoking status, pack years of smoking, total cholesterol, HDL cholesterol, hypertension, DM, use of statin medications, C-reactive protein (CRP), D-dimer, number of cardiovascular diseases, and leg symptoms were included in the initial model. Baseline ABI, age, gender, ethnicity, leg symptom classification, and diabetes were forced into the final models. $P < .05$ was considered statistically significant. A multiplicative term, DM*baseline ABI was used to test for interaction in the final models for the entire cohort ($P < .1$ was considered statistically significant).

Sensitivity analysis was conducted to determine the effect of excluding limbs with revascularization during four year follow-up. These included: (1) carrying forward ABI values obtained prior to revascularization; and (2) using imputed ABI values calculated from imputation and variance estimation software (IVEware, University of Michigan, Ann Arbor, MI). All analyses were conducted on SAS version 9.3, were limb specific, and conducted separately for the lower and higher ABI limb.

Results

Among 566 participants from the WALCS and WALCS II cohorts who met eligibility criteria for our study, 72.3% were recruited from the vascular lab, and 27.7% from internal medicine practices. The mean age was 71 + 8 years, and 53% had PAD (Table 1). Compared to participants without PAD, those with PAD had lower baseline ABI, were older, less likely to be African American, more likely to be male, and to be diagnosed with DM.

When examining the leg with the lower ABI at baseline, mean (SD) baseline ABI values were 0.70 (0.13) for participants with both PAD and DM, 0.67 (0.14) for participants with only PAD, 1.10 (0.13) for participants with only DM, and 1.10 (0.10) for participants neither PAD nor DM (Table 2). After adjusting for age, gender, and baseline ABI, corresponding ABI changes by group from baseline to 4-year follow-up were -0.02 (95% CI: -0.08, 0.03), -0.04 (95% CI: -0.09, 0.001), +0.05 (95% CI: -0.01, 0.11), and +0.05 (95% CI: 0.02, 0.09) respectively. Compared to participants with neither PAD nor DM, participants with only PAD showed significant ABI decline ($P < 0.01$) while decline in participants with both PAD and DM was borderline non-significant ($P = .06$). Also, the change in ABI for those with only DM was not significantly different from those with neither PAD nor DM ($P = .99$). For the leg with higher ABI at baseline, the mean (SD) baseline ABI was 0.84 (0.25), for participants with PAD and DM, 0.84 (0.18) for participants with only PAD, 1.15 (0.13) for participants with only DM, and 1.15 (0.11) for participants with neither PAD nor DM (Table 2). After adjusting for age, gender, and baseline ABI, corresponding ABI changes at four-year follow up were -0.07 (95% CI: -0.11, -0.03), -0.07 (95% CI: -0.01, -0.04), +0.02 (95% CI: -0.04, 0.07), and -0.02 (95% CI: -0.04, 0.01) respectively. Compared to participants with neither PAD nor DM, the ABI change in participants with both PAD and DM was borderline non-significant, while participants with only PAD showed significant decline. In both lower and higher ABI leg analyses, no significant differences were observed when comparing participants with both PAD and DM vs. participants with only PAD, though in the higher leg the coefficient was positive for DM only and negative for neither DM nor PAD ($P = .23$ for difference).

Table 3 shows hazard ratios for the likelihood of the combined outcome of ABI decline ≥ 0.15 or revascularization from baseline to four year follow-up. For the lower leg ABI, compared to participants with neither PAD nor DM, participants with both PAD and DM along with those with only PAD were more likely to have a ≥ 0.15 decline in their ABI or revascularization during follow up (HR=3.05, 95%CI: 1.56–5.95 and HR=3.25, 95%CI: 1.73–6.10 respectively). Participants with only DM were also more likely to have either ABI decline ≥ 0.15 or revascularization during the same period. Similar results were observed for the higher ABI leg.

Table 4a shows results of multivariable adjusted analyses relating baseline ABI, age, gender, ethnicity, body mass index (BMI), cigarette smoking status, pack years of smoking cigarettes, total cholesterol, HDL cholesterol, CRP, hypertension, DM, use of statin medications, D-dimer, number of cardiovascular diseases, leg symptoms of pain on exertion or at rest, intermittent claudication, and other atypical leg pain with change in the ABI over four years. PAD, older age, and higher levels of D-dimer were each independently associated with progression to lower ABI at four-year follow up. DM was not associated with ABI change ($p = 0.98$), and in fact the coefficient was positive, suggesting a slight increase in the ABI in the whole cohort and separately in the PAD and non-PAD groups. Test for DM interaction with baseline ABI [DM*baseline ABI] was not significant ($P=0.11$). Separate analyses were conducted for participants with and without PAD. In participants with PAD, older age, and elevated D-dimer were significantly associated with lower ABI at four-year follow up (Table 4a). In participants without PAD, more pack years smoking, and greater number of cardiovascular diseases were associated with lower ABI at four-year follow up. In the leg with higher ABI (Table 4b), after the same adjustments as described above, PAD, lower BMI, higher levels of total cholesterol, use of statin medications, and higher levels of D-dimer were independently associated with lower ABI at four-year follow up, while more pack years of smoking, lower HDL cholesterol were borderline non-significant ($p = 0.054$ and 0.059 respectively). DM was not significantly associated with ABI change over four years ($p = 0.61$), and test for DM interaction with baseline ABI [DM*baseline ABI] was negative ($p = 0.56$). When only participants with PAD were evaluated, more pack-years smoking and elevated D-dimer were independently associated with lower ABI over four years, while older age was borderline non-significant. In non-PAD participants, the leg symptom of intermittent claudication was associated with increased ABI over four years.

Sensitivity analysis evaluating the impact of excluding limbs with revascularization during follow-up did not yield significantly different results (not shown). In other sensitivity analysis (also not shown), when considering the higher leg ABI, compared to participants with neither DM nor PAD, those with both DM and PAD had the greatest hazard of ABI increase ≥ 0.15 (HR=1.92, 95%CI: 0.98 to 3.78). However, this association was borderline non-significant ($P = 0.058$). Hazards for those with only DM (HR=1.67, 95%CI: 0.82 to 3.39) and only PAD (HR=1.22, 95% CI: 0.66 to 2.27) were not significant.

Discussion

Among individuals diagnosed with PAD, there was a suggestion in our data that participants who also had DM have a smaller ABI decline at four-year follow-up. In our cohort, independent factors associated with ABI decline in the leg with the lower ABI were a diagnosis of PAD, older age, and, elevated D-dimer. ABI decline at four-year follow-up in the leg with higher ABI was similarly associated with a diagnosis of PAD and elevated D-dimer, but also lower BMI, abnormal lipids, and the use of statin medications. DM was not significantly associated with progression in either the lower or higher leg ABI in multivariable analysis, likely due to the antagonistic effects of DM promoting both PAD and stiff lower extremity arteries.

DM is a very strong independent risk factor for critical limb ischemia and amputation, as well as incident PAD in population studies.^{1,22,23} Although a report from a vascular laboratory study indicated that DM did predict ABI decline over an average of 4.6 years of follow-up, the authors excluded follow-up ABI values >1.15 because of likely arterial stiffening.²⁴ A later report from the same vascular laboratory showed that DM was not related to ABI decline, but was highly and significantly related to a toe-brachial index (TBI) decline.²⁵ Since the TBI is much less sensitive to arterial stiffening than the ABI, this strongly suggests arterial stiffening in persons with DM during follow-up. Of interest is that in the Cardiovascular Health Study, DM was associated with incident clinical PAD, but not associated with ABI decline over time, again strongly suggesting that DM influences both atherosclerosis and arterial stiffening and that its effects on atherosclerotic PAD may be missed if evaluated using serial ABI measurements.²² Stiffening may mask the progression of obstructive disease leading to reduced ABI decline, no ABI changes, or slight ABI increases over time. We postulated that due to arterial stiffening, individuals with both PAD and DM might see either an increase in ABI over time or a reduced rate of decline in their ABI over 4 years. We also postulated that this observation would be more prevalent in the higher ABI leg. Though suggestive our results were not supportive of the latter.

Consistent with this hypothesis, our results demonstrate that the largest decline over four years was observed in participants with only PAD. When considering the leg with the lower ABI value (generally used to determine PAD status), these participants had a lower ABI at baseline and a greater decline at four-year follow up compared to participants with both PAD and DM, who only had half as much decline.

After adjustments for baseline ABI, older age, and abnormal lipids were independently associated with ABI decline in our study. More pack years smoking was independently associated with decline in higher leg ABI, for participants with PAD. Smoking cessation is a primary component in the management of PAD because of its strong association with disease incidence and severity.¹

Higher D-dimer levels were associated with ABI decline for both the lower and higher leg ABI. Others have reported the predictive role of D-dimer in the incidence, severity, and progression of PAD.^{26,27} In fact, in our stratified analysis based on PAD status, elevated level of D-dimer was the only consistent predictor of ABI decline. Elevated plasma levels of D-dimer may reflect active ongoing atherosclerotic disease progression.²⁶

This study has some limitations. Participants were recruited from vascular labs in academic medical centers, and results may not be generalizable to other settings. Four-year follow up may be too short a time interval to fully characterize ABI change. Limbs with revascularizations prior or during the follow up period were excluded from the analysis. For individual with revascularizations in one limb only, the limb without intervention was included in the analysis. Revascularization in one leg may unmask symptoms of intermittent claudication in the other leg. Individuals with revascularizations in both limbs were excluded from the analysis. It is likely that these individuals had increased disease severity, and their exclusion would bias our associations towards the null. Taken together, the overall

modest ABI decline in PAD may reflect exclusion of limbs with the greatest burden of lower extremity atherosclerosis.

Conclusions

In our cohort, CVD risk factors of older age and elevated D-dimer, were associated with ABI decline at four year follow-up in persons with PAD. DM was not associated with longitudinal ABI decline. This may reflect its unique opposing effects on ABI by promoting both occlusive atherosclerotic disease and arterial stiffening. This may limit the prognostic value of the ABI in diabetic patients.

Acknowledgments

Funding Source: T32 HL079891, NIH-NHLBI Training Grant "UCSD Integrated Cardiovascular Epidemiology Fellowship"

References

1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg.* 2007; 33(Suppl 1):S1–75.
2. Lijmer JG, Hunink MG, van den Dungen JJ, Loonstra J, Smit AJ. ROC analysis of noninvasive tests for peripheral arterial disease. *Ultrasound Med Biol.* 1996; 22(4):391–398. [PubMed: 8795165]
3. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. *N Engl J Med.* 1992 Feb 6; 326(6): 381–386. [PubMed: 1729621]
4. Ogren M, Hedblad B, Isacson SO, Janzon L, Jungquist G, Lindell SE. Non-invasively detected carotid stenosis and ischaemic heart disease in men with leg arteriosclerosis. *Lancet.* 1993 Nov 6; 342(8880):1138–1141. [PubMed: 7901475]
5. Leng GC, Fowkes FG, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. *BMJ.* 1996 Dec 7; 313(7070): 1440–1444. [PubMed: 8973232]
6. McDermott MM, Greenland P, Liu K, Guralnik JM, Celic L, Criqui MH, et al. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. *Ann Intern Med.* 2002 Jun 18; 136(12):873–883. [PubMed: 12069561]
7. McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. *JAMA J Am Med Assoc.* 2004 Jul 28; 292(4):453–461.
8. McDermott MM, Guralnik JM, Tian L, Liu K, Ferrucci L, Liao Y, et al. Associations of borderline and low normal ankle-brachial index values with functional decline at 5-year follow-up: the WALCS (Walking and Leg Circulation Study). *J Am Coll Cardiol.* 2009 Mar 24; 53(12):1056–1062. [PubMed: 19298919]
9. Everhart JE, Pettitt DJ, Knowler WC, Rose FA, Bennett PH. Medial arterial calcification and its association with mortality and complications of diabetes. *Diabetologia.* 1988 Jan; 31(1):16–23. [PubMed: 3350219]
10. Lehto S, Niskanen L, Suhonen M, Rönnemaa T, Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. *Arterioscler Thromb Vasc Biol.* 1996 Aug; 16(8):978–983. [PubMed: 8696962]
11. Brooks B, Dean R, Patel S, Wu B, Molyneaux L, Yue DK. TBI or not TBI: that is the question. Is it better to measure toe pressure than ankle pressure in diabetic patients? *Diabet Med J Br Diabet Assoc.* 2001 Jul; 18(7):528–532.

12. McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. *JAMA J Am Med Assoc.* 2001 Oct 3; 286(13):1599–1606.
13. McDermott MM, Sufit R, Nishida T, Guralnik JM, Ferrucci L, Tian L, et al. Lower extremity nerve function in patients with lower extremity ischemia. *Arch Intern Med.* 2006 Oct 9; 166(18): 1986–1992. [PubMed: 17030832]
14. McDermott MM, Hoff F, Ferrucci L, Pearce WH, Guralnik JM, Tian L, et al. Lower extremity ischemia, calf skeletal muscle characteristics, and functional impairment in peripheral arterial disease. *J Am Geriatr Soc.* 2007 Mar; 55(3):400–406. [PubMed: 17341243]
15. Shadman R, Criqui MH, Bundens WP, Fronck A, Denenberg JO, Gamst AC, et al. Subclavian artery stenosis: prevalence, risk factors, and association with cardiovascular diseases. *J Am Coll Cardiol.* 2004 Aug 4; 44(3):618–623. [PubMed: 15358030]
16. Guralnik, JM.; Fried, LP.; Simonsick, EM.; Kasper, JD.; Lafferty, ME., editors. *The Women's Health and Aging Study: Health and Social Characteristics of Older Women With Disability.* Bethesda, MD: NIH Pub; 1995.
17. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. *Clin Chem.* 1974 Apr; 20(4):470–475. [PubMed: 4818200]
18. Sugiuchi H, Uji Y, Okabe H, Irie T, Uekama K, Kayahara N, et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. *Clin Chem.* 1995 May; 41(5):717–723. [PubMed: 7729051]
19. Criqui MH, Denenberg JO, Bird CE, Fronck A, Klauber MR, Langer RD. The correlation between symptoms and non-invasive test results in patients referred for peripheral arterial disease testing. *Vasc Med Lond Engl.* 1996; 1(1):65–71.
20. Novo S, Coppola G, Milio G. Critical limb ischemia: definition and natural history. *Curr Drug Targets Cardiovasc Haematol Disord.* 2004 Sep; 4(3):219–225. [PubMed: 15379613]
21. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. *Circulation.* 2012 Dec 11; 126(24):2890–2909. [PubMed: 23159553]
22. Kennedy M, Solomon C, Manolio TA, Criqui MH, Newman AB, Polak JF, et al. Risk factors for declining ankle-brachial index in men and women 65 years or older: the Cardiovascular Health Study. *Arch Intern Med.* 2005 Sep 12; 165(16):1896–1902. [PubMed: 16157835]
23. Allison MA, Cushman M, Solomon C, Aboyans V, McDermott MM, Goff DC Jr, et al. Ethnicity and risk factors for change in the ankle-brachial index: the Multi-Ethnic Study of Atherosclerosis. *J Vasc Surg.* 2009 Nov; 50(5):1049–1056. [PubMed: 19628357]
24. Bird CE, Criqui MH, Fronck A, Denenberg JO, Klauber MR, Langer RD. Quantitative and qualitative progression of peripheral arterial disease by non-invasive testing. *Vasc Med Lond Engl.* 1999; 4(1):15–21.
25. Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronck A. Risk factors for progression of peripheral arterial disease in large and small vessels. *Circulation.* 2006 Jun 6; 113(22):2623–2629. [PubMed: 16735675]
26. Tzoulaki I, Murray GD, Price JF, Smith FB, Lee AJ, Rumley A, et al. Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the Edinburgh Artery Study. *Am J Epidemiol.* 2006 Feb 15; 163(4):334–341. [PubMed: 16357107]
27. Mota APL, de Castro Santos MER, Lima e Silva F, das C, de Carvalho Schachnik NC, de Oliveira Sousa M, das Graças Carvalho M. Hypercoagulability markers in patients with peripheral arterial disease: association to ankle-brachial index. *Angiology.* 2009 Nov; 60(5):529–535. [PubMed: 19015166]

Table 1

Baseline clinical characteristics among participants with and without peripheral arterial disease

Cohort (N=566)	Participants without PAD Mean (SD), % (N) N=266	Participants with PAD Mean (SD), % (N) N=300
Baseline ABI (lower leg)	1.10 (0.10)	0.68 (0.14) ^a
Baseline ABI (higher leg)	1.15 (0.11)	0.84 (0.21) ^a
Four-year follow up ABI (lower leg)	1.10 (0.17)	0.70 (0.25) ^a
Four year follow up ABI (higher leg)	1.12 (0.16)	0.79 (0.28) ^a
Age (years)	69 (7)	72 (8) ^a
Male	44 (117)	57 (172) ^a
African American	23 (62)	15 (45) ^a
Body mass index (kg/m ²)	29 (6)	28 (5)
Current smoker	6 (16)	13 (40) ^a
Pack-years of smoking	15 (21)	37 (35) ^a
Total cholesterol, mg/dL	179 (37)	178 (37)
HDL cholesterol, mg/dL	50 (18)	45 (17) ^a
C-reactive protein, mg/L	4 (6)	4 (6)
Hypertension	68 (179)	78 (234) ^a
Diabetes mellitus type 2	18 (48)	29 (87) ^a
Diet controlled	29 (14)	30 (26)
Oral hypoglycemic medication	40 (19)	36 (31)
Insulin	31 (15)	34 (30)
Statin use	27 (71)	47 (142) ^a
D-dimer, ng/mL	0.57 (0.39)	0.83 (1.36) ^a
Number of cardiovascular disease (0–4)	0.44 (0.78)	0.81 (1.02) ^a
Leg symptom No pain	62 (163)	18 (55) ^a
Leg symptom Pain on exertion or at rest ^b	25 (65)	19 (56)
Leg symptom Intermittent claudication	2 (4)	27 (81) ^a
Leg symptom Other atypical leg pain	12 (33)	36 (107) ^a

Cohort = participants contributing at least one leg to the study

ABI = ankle-brachial index, PAD = peripheral arterial disease (defined by lower leg ABI < 0.9)

^aP-value < 0.05 for comparisons of baseline clinical characteristics^bLeg symptom Pain on exertion or at rest is different from critical limb ischemia

Table 2

Average change in ankle-brachial index from baseline to four year follow up

	N	Mean (SD)	Baseline ABI	Average ABI change at Four-years (95% CI) ^a	P-value (Pair-wise) ^b	P-value (Model)
<u>Lower ABI leg (N=489)</u>						
PAD and DM	58	0.70	(0.13)	-0.02 (-0.08, 0.03)	0.06	0.07
Only PAD	166	0.67	(0.14)	-0.04 (-0.09, 0.001)	< 0.01	
Only DM	48	1.10	(0.13)	0.05 (-0.01, 0.11)	0.99	
Neither (PAD nor DM)	217	1.10	(0.10)	0.05 (0.02, 0.09)	Reference	
<u>Higher ABI leg (N=555)</u>						
PAD and DM	83	0.84	(0.25)	-0.07 (-0.11, -0.03)	0.054	< 0.05
Only PAD	208	0.84	(0.18)	-0.07 (-0.10, -0.04)	< 0.05	
Only DM	47	1.15	(0.13)	0.02 (-0.04, 0.07)	0.23	
Neither (PAD nor DM)	217	1.15	(0.11)	-0.02 (-0.04, 0.01)	Reference	

ABI = ankle brachial index, PAD = peripheral arterial disease, DM = diabetes mellitus type 2

^a Adjustments for age, gender, and baseline ABI^b PAD and DM vs. Only PAD (p = 0.48 lower ABI leg; p = 0.92 higher ABI leg)

Table 3

Hazard ratio for ankle-brachial index decline greater than or equal to 0.15 or revascularization from baseline to four year follow up

	N	Total number of events	ABI decline ≥ 0.15	Vascularized events	Hazard Ratio (95% CI) ^a	P-value (Pair-wise) ^b	P-value (Model)
<u>Lower ABI leg (N=808)</u>							
PAD and DM	124	32	23	9	3.05 (1.56 to 5.95)	<0.01	<0.01
Only PAD	294	83	63	20	3.25 (1.73 to 6.10)	<0.01	
Only DM	83	20	20	0	1.81 (1.06 to 3.09)	<0.05	
Neither (PAD nor DM)	307	46	45	1	1.00 (ref)		
<u>Higher ABI leg (N=953)</u>							
PAD and DM	185	69	58	11	2.35 (1.59 to 3.47)	<0.01	<0.01
Only PAD	379	141	115	26	2.12 (1.50 to 3.00)	<0.01	
Only DM	83	32	32	0	1.78 (1.18 to 2.70)	<0.01	
Neither (PAD nor DM)	306	81	80	1	1.00 (ref)		

ABI = ankle brachial index, PAD = peripheral arterial disease, DM = diabetes mellitus type 2

^a Adjustments for age, gender, and baseline ABI

^b PAD and DM vs. Only PAD (p = 0.75 lower ABI leg; p = 0.50 higher ABI leg)

Table 4a

Multivariable associations of lower leg ankle brachial index change over four years

Model	Cohort (N=416) Beta	PAD (N=188) Beta	Non PAD (N=263) Beta
Baseline ABI (leg with lowest ABI) ^b	-0.08 ^a	-0.09 ^a	-0.07 ^a
PAD	-0.08 ^a	NA	NA
Age (years) ^b	-0.02 ^a	-0.03 ^a	-0.02
Male gender ^b	0.01	0.007	0.03
African American ^b	0.01	0.014	0.02
Pack-years of smoking	NA	NA	-0.03 ^a
Diabetes mellitus type 2 ^{b, c}	0.001	0.004	0.01
D-dimer, ng/mL	-0.03 ^a	-0.03 ^a	NA
Number of cardiovascular diseases	NA	NA	-0.03 ^a
Leg symptoms ^b			
No leg pain	Reference	Reference	Reference
Leg pain on exertion or at rest	0.003	0.04	-0.03
Intermittent Claudication	-0.05	-0.06	0.12
Other leg pain	-0.02	-0.01	-0.04
Model R2	0.08 ^a	0.11 ^a	0.09 ^a

Cohort = participants contributing at least one leg to the study, N = number PAD = peripheral artery disease (defined by lower leg ABI < 0.9), ABI = ankle brachial index

Model = Stepwise multi-variable linear regression (p < .1 criterion), NA = not retained in the model N = Numbers from step wise selection. For the 566 participants the following values were missing BMI 3; smoking 2; total cholesterol/HDL 53; hypertension 2; CRP 82; D-dimer 84; leg symptom 2

Beta = Adjustments for baseline ABI, age, gender, African American ethnicity, body mass index, cigarette smoking status, pack years of smoking cigarettes, total cholesterol, HDL cholesterol, C-reactive protein, hypertension, diabetes mellitus type II, use of statin medications, D-dimer, number of cardiovascular diseases, leg symptoms of pain on exertion or at rest (different from critical limb ischemia), intermittent claudication, and other leg pain

^aP-value 0.05

^bVariables forced into the model

^cDM*Baseline ABI interaction (P-value = 0.11)

Table 4b

Multivariable associations of higher leg ankle brachial index change over four years

Model	Cohort (N=466)	PAD (N=242)	Non PAD (N=263)
	Beta	Beta	Beta
Baseline ABI (leg with higher ABI) ^b	-0.05 ^a	-0.06 ^a	-0.03
PAD	-0.05 ^a	NA	NA
Age (years) ^b	-0.01	-0.02	-0.002
Male gender ^b	0.002	0.01	-0.01
African American ^b	-0.01	-0.04	0.02
Body Mass Index (Kg/m2)	0.02 ^a	NA	NA
Pack-years of smoking	-0.02	-0.02 ^a	NA
Total cholesterol	-0.02 ^a	NA	NA
HDL cholesterol, mg/dL	0.02	NA	NA
Diabetes mellitus type 2 ^{b, c}	-0.01	-0.03	0.04
Statin use	-0.04 ^a	NA	NA
D-dimer, ng/mL	-0.02 ^a	-0.02 ^a	NA
Leg symptoms ^b			
No leg pain	Reference	Reference	Reference
Leg pain on exertion or at rest	0.01	0.04	-0.01
Intermittent Claudication	-0.02	-0.05	0.17 ^a
Other leg pain	-0.01	-0.02	-0.03
Model (R2)	0.10 ^a	0.11 ^a	0.07 ^a

Cohort = participants contributing at least one leg to the study, N = number PAD = peripheral artery disease (defined by lower leg ABI < 0.9), ABI = ankle brachial index

Model = Stepwise multi-variable linear regression (p < .1 criterion), NA = not retained in the model N = Numbers from step wise selection. For the 566 participants the following values were missing BMI 3; smoking 2; total cholesterol/HDL 53; hypertension 2; CRP 82; D-dimer 84; leg symptom 2

Beta = Adjustments for baseline ABI, age, gender, African American ethnicity, body mass index, cigarette smoking status, pack years of smoking cigarettes, total cholesterol, HDL cholesterol, C-reactive protein, hypertension, diabetes mellitus type II, use of statin medications, D-dimer, number of cardiovascular diseases, leg symptoms of pain on exertion or at rest (different from critical limb ischemia), intermittent claudication, and other leg pain

^aP-value 0.05

^bVariables forced into the model

^cDM*Baseline ABI interaction (P-value = 0.56)